A Study YL201 in Patients With Selected Advanced Solid Tumors

Inclusion Criteria:

• Informed of the trial before the start of the trial and voluntarily sign their nameand date on the ICF.

• Age ≥18 years old and ≤75 years old

• Histologically or cytologically confirmed at diagnosis of NSCLC/SCLC/NPC/ESCC /mCRPC/HNSCC/Sarcoma/PDAC/HCC/BTC

• At least one extracranial measurable lesion according to RECIST 1.1.

• Archived or fresh tumor tissue samples can be provided.

• Eastern Cooperative Oncology Group - performance scale (ECOG PS) score of 0 or 1.

• Female subjects with fertility must agree to take high-efficiency contraceptivemeasures from screening to whole study period and within at least 6 months afterlast administration of investigational drug. Male subjects must agree to takehigh-efficiency contraceptive measures from screening to whole study period andwithin at least 6 months after last administration of investigational drug.

• Life expectancy ≥3 months.

• Capable or willing to observe the visits and procedures stipulated in studyprotocol.

Exclusion Criteria:

• Prior treatment with products targeting B7H3 (including antibodies, antibody-drugconjugate [ADC], chimeric antigen receptor T cells [CAR-T], and other drugs).

• Prior treatment with topoisomerase 1 inhibitors or ADC based on topoisomerase 1inhibitors.

• Participation in another clinical trial meanwhile, except observatory (non-interventional) clinical trial or at follow-up period of interventional study.

• Washout period of previous anticancer treatment was insufficient before firstadministration of investigational drug.

• Major surgery (excluding diagnostic surgery) within 4 weeks before firstadministration of investigational drug or likely to require major surgery during thestudy.

• History of allogenic bone marrow transplantation or solid organ transplantation.

• Treatment with systemic steroid (Prednisone >10 mg/d or equivalent drugs) or otherimmunosuppressive drugs within 2 weeks before first administration ofinvestigational drug.

• Live vaccination within 4 weeks before first administration of investigational drugor likely to require live vaccine inoculation during the study.

• Evidence of leptomeningeal metastasis or carcinomatous meningitis.

• Evidence of brain metastasis or spinal cord compression.

• Evidence of cardiovascular disease with uncontrolled state or clinical significance.

• Clinically significant concomitant lung disease.

• Diagnosed as Gilbert syndrome.

• Complicated with uncontrolled third-space effusion .

• History of gastrointestinal perforation and/or fistula within 6 months before firstadministration.

• History of serious infection (Grade ≥3 of NCI CTCAE) before first administration.

• Known as infection with human immunodeficiency virus (HIV).

• Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

• History of any other primary malignant tumor within 5 years before firstadministration of investigational drug.

• The toxicity of previous anticancer treatment is not resolved.

• History of serious hypersensitive reactions to drug substance, inactive compositionsof preparations or other monoclonal antibodies.

• Breastfeeding women. Or women confirmed as pregnant through pregnancy test within 3days before first administration.

• Any disease, medical state, organ/system dysfunction or social state considered byinvestigators as possibly interfering the subject's capability for ICF signing,producing adverse influence on the subject's capability for cooperation and studyparticipation or influencing the interpretation of study results. Including but notlimited to mental disease or substance/alcohol abuse.